Insomnia News and Research

Latest Insomnia News and Research

Orexo reports net revenues of MSEK 55.2 for second quarter 2011

OREXO: STRONG SALES INCREASE FOR ABSTRAL. For the period. Royalty revenues from Abstral sales in Europe rose to MSEK 30.4.

10 Aug 2011

Allergan receives positive opinion from Irish Medicines Board for BOTOX

Allergan is pleased to announce that BOTOX has received a positive opinion from the Irish Medicines Board for the management of urinary incontinence in adults with neurogenic detrusor overactivity (NDO) resulting from neurogenic bladder due to stable sub-cervical spinal cord injury, or multiple sclerosis.

8 Aug 2011

Cadence confirms FDA dosing recommendations for OFIRMEV

Cadence Pharmaceuticals, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) approved dosing recommendations for OFIRMEV (acetaminophen) injection remains 4,000 mg per day for adults and adolescents weighing at least 50 kg.

29 Jul 2011

FDA accepts peginesatide NDA for anemia associated with CKD

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for peginesatide (formerly known as Hematide™) for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.

27 Jul 2011

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc., resubmitted two New Drug Applications to the United States Food and Drug Administration for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.

26 Jul 2011

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Biogen Idec announced today it has received conditional approval from the European Commission for FAMPYRA® (prolonged-release fampridine tablets) to improve walking in adult patients with multiple sclerosis who have walking disability.

25 Jul 2011

Health Canada approves Valeant's NDA for Sublinox to treat insomnia

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Valeant Canada Limited, has received notice that the New Drug Submission for Sublinox has been approved from the Canadian regulatory authority Health Canada.

25 Jul 2011

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA and ACTIQ.

22 Jul 2011

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Janssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO and THRIVE, comparing the efficacy, safety and virology profile of its non-nucleoside reverse transcriptase inhibitor EDURANT tablets versus efavirenz (EFV) in antiretroviral treatment-naive, HIV-1-infected adults.

20 Jul 2011

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the submission of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for VELCADE® (bortezomib) for injection to add overall survival data after a five-year follow up to the product label.

20 Jul 2011

Insight into global incidence and prevalence of mild cognitive impairment

New research reported today in Paris at the Alzheimer's Association International Conference 2011 (AAIC 2011) offers insight on the global incidence and prevalence of mild cognitive impairment (MCI) – a condition involving problems with memory or another mental function severe enough to be noticeable to the affected person or to others but not serious enough to interfere with daily life.

19 Jul 2011

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

Merck, known as MSD outside the United States and Canada, today announced final results from a Phase II clinical study, extending out to 240 weeks, of its integrase inhibitor ISENTRESS® (raltegravir) Tablets in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients.

18 Jul 2011

Transcept decreases workforce following FDA news on Intermezzo NDA

Transcept Pharmaceuticals, Inc. announced today plans to reduce operating expenses by eliminating approximately 45% of its workforce following notification from the U.S. Food and Drug Administration (FDA) that the resubmitted New Drug Application (NDA) for Intermezzo, the company's lead product candidate, cannot be approved in its present form.

16 Jul 2011

Transcept receives FDA Complete Response Letter for Intermezzo NDA

Transcept Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the resubmitted New Drug Application (NDA) for Intermezzo.

15 Jul 2011

Scientists track public health trends through Twitter

Twitter allows millions of social media fans to comment in 140 characters or less on just about anything: an actor's outlandish behavior, an earthquake's tragic toll or the great taste of a grilled cheese sandwich.

8 Jul 2011

First ever clinical study using Brainwave Optimization technology to treat insomnia

Insomnia is the most prevalent sleep disorder, affecting up to 50 percent of the adult population in the United States on a weekly basis.

1 Jul 2011

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

Omeros Corporation today reported that it has identified compounds that interact with orphan G protein-coupled receptors (GPCRs) P2Y8 and OPN4. P2Y8 (also known as P2RY8) is associated with acute lymphoblastic leukemia (ALL), an aggressive cancer of the white blood cells.

27 Jun 2011

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor, NBI-98854.

24 Jun 2011

Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint

Pfizer Inc. announced today that top-line results for Lyrica Study A0081107 - Central Neuropathic Pain Following Spinal Cord Injury - demonstrated that the study met its primary endpoint: positive efficacy in reducing Central Neuropathic Pain following Spinal Cord Injury with Lyrica compared to placebo.

22 Jun 2011

Rocking allows for better sleep – even in insomniac adults!

A new study shows that people tend to sleep faster and even achieve better quality sleep if they are gently swayed. The findings may explain why parents instinctively rock babies to sleep, and why we find it so easy to nod off when slumped in a rocking chair, they add

21 Jun 2011

Insomnia News and Research

Latest Insomnia News and Research

Orexo reports net revenues of MSEK 55.2 for second quarter 2011

Allergan receives positive opinion from Irish Medicines Board for BOTOX

Cadence confirms FDA dosing recommendations for OFIRMEV

FDA accepts peginesatide NDA for anemia associated with CKD

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Health Canada approves Valeant's NDA for Sublinox to treat insomnia

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Insight into global incidence and prevalence of mild cognitive impairment

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

Transcept decreases workforce following FDA news on Intermezzo NDA

Transcept receives FDA Complete Response Letter for Intermezzo NDA

Scientists track public health trends through Twitter

First ever clinical study using Brainwave Optimization technology to treat insomnia

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint

Rocking allows for better sleep – even in insomniac adults!

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Insomnia News and Research

Latest Insomnia News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in